BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Induced Pluripotent Stem Cell News Round-Up| February 15-22, 2015
iPSC News Round-Up February 2014

Induced Pluripotent Stem Cell News Round-Up| February 15-22, 2015

February 20, 2015 By Cade Hildreth (CEO) Leave a Comment

The induced pluripotent stem cell (iPSC) industry is a rapidly evolving area.  Since the discovery of iPSCs in 2006, there have been a number of important market events that have occurred, including the first ever clinical trial in humans that was initiated in August 2013 to investigate iPSC-derived cell sheets for restoring vision, as well as large funding awards, major initial public offerings (IPOs), critical patent challenges, and more.

Discover class-defining bioproduction tools.

Every month there are major events occurring in the sector that shift industry dynamics. Often, these events are announcements of technical or scientific advancements.  Sometimes there are announcements of major industry alliances. Occasionally, there are announcements of a new industry competitor, a major milestone, or a significant funding award.

For those of us interested in the induced pluripotent stem cell (iPSC) industry, tracking these shifting dynamics is of paramount importance.  This post covers the most significant iPSC industry news events for the week of February 15-21, 2015.

bitbio

iPSC News Round-Up for February 15-22, 2015

1. New partnership aims to create stem cell resource to study psychiatric disorders [February 20, 2015]

The New York Stem Cell Foundation (NYSCF) and the Stanley Center at the Broad Institute of MIT and Harvard are partnering to create a foundational stem cell resource to study psychiatric disorders through the production of induced pluripotent stem (iPS) cell lines from individuals with schizophrenia and other psychiatric disorders.

Read More…

iPSC-derived cardiomyocte therapy
2.  In vitro platform for antimalarial testing developed from stem cells [February 19, 2015]

Lab-grown liver cells derived from induced pluripotent stem cells may allow for personalized testing on antimalarial drugs and vaccines, according to recent data. “The platform can be used for testing candidate drugs that act against the parasite in the early liver stages, before it causes disease in the blood and spreads back to the mosquito vector,” says Sangeeta Bhatia, MD, PhD, of MIT and Brigham and Women’s Hospital. Bhatia and colleagues reprogrammed human skin cells to generate iPSCs, which were then adapted to model cells from the liver using a 20-day in vitro differentiation protocol.

Pluristyx

Read More…

* NOTE: Cellular Dynamics International (CDI) also published a press release about this iPSC news topic on February 11, 2015, titled “iCell Hepatocytes Enable Malaria-in-a-Dish Studies.” In this press release, CDI wrote  that their iCell® Hepatocytes, or human liver cells manufactured from iPSCs, had been used as a malaria-in-a-dish model to test anti-malarial drug candidates.

3.  Cynata Therapeutics achieves stem cell manufacturing breakthrough [February 19, 2015]

Cynata Therapeutics has achieved a breakthrough in the manufacture of stem cells and is set to scale up manufacturing of its mesenchymal stem cells derived from iPSCs for therapeutic use.

The company’s lead Cymerus™ stem cell manufacturing process has now been successfully validated through extensive trials at Waisman Biomanufacturing in Madison, Wisconsin. The trials confirmed this state-of-the-art stem cell manufacturing process is capable of producing MSCs for therapeutic application, consistently, efficiently and economically, in a Good Manufacturing Practice (GMP) production environment.

Importantly, the Cymerus™ process uses an effectively limitless starting material – a bank of induced pluripotent stem cells (iPSCs) – and a patent-protected process to derive MSCs for commercial use.

Read More…

4.  Cellular Dynamics Manufactures cGMP HLA “Superdonor” Stem Cell Lines to Enable Cell Therapy With Genetic Matching [February 15, 2015]

Cellular Dynamics International, Inc. (CDI) announced that it has manufactured, under current Good Manufacturing Practices (cGMP), stem cell lines from two HLA “superdonors.” HLA superdonors are individuals whose genetic HLA (human leukocyte antigens) profiles make their cells or tissues more compatible for donation to unrelated patients. As the first announced HLA superdonor master cell bank in the world, and the first produced under cGMP, these cell lines will enable a new area of cell therapy research using HLA matching.

CDI manufactured the HLA superdonor cell lines from blood samples collected from eligible anonymous donors.  The induced pluripotent stem cell (iPSC) lines made from the donor samples are pluripotent, meaning they can be used to produce virtually any cell type in the human body.

Read More…

Future iPSC News Round-Ups

To receive future induced pluripotent stem cell (iPSC) industry news round-ups and stay informed about major events, sign-up below.

 

About Us

BioInformant is the only research firm that has served the stem cell sector since it emerged. Our management team comes from a BioInformatics background – the science of collecting and analyzing complex genetic codes – and applies these techniques to the field of mark research. BioInformant has been featured on news outlets including the Wall Street Journal, Nature Biotechnology, Medical Ethics, CBS News, and the California Institute for Regenerative Medicine (CIRM).

cropped-BioInformant-Logo-As-Featured-On.jpg

Serving Fortune 500 leaders that include GE Healthcare, Pfizer, Goldman Sachs, Beckton Dickinson, and Thermo Fisher Scientific, BioInformant is your global leader in stem cell industry data.

To learn more about emerging trends and opportunities within the iPSC industry, view the “Complete 2015-16 Induced Pluripotent Stem Cell Industry Report” now.

Complete 2015-16 Induced Pluripotent Stem Cell (iPSC) Industry Report

Rate this post

Filed Under: iPS Cells, Stem Cells Tagged With: cell therapy, current events, iPSC, market update, stem cells

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Tell Us What You Think! Cancel reply

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Featured Posts

PolarityTE RMAT

PolarityTE Announces FDA RMAT Awarded to Its Designation Granted to SkinTE®

Advanced Therapy | What is a RMAT Designation (and Who Has One)?

What Is An RMAT? List of Publicly Announced RMAT Designations (64)

i-peaces-cell-manufacturing

I Peace accelerates allogeneic iPSC-derived cell therapies with a high throughput method to identify a large number of donors with specific HLA haplotypes

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.